General Name: Recombinant Human Interferon α1b inhalation

       Anticipated Application: Pediatric respiratory viral infections,such as pediatric RSV viral                      pneumonia and bronchiolitis

       Product Features:

           1.The only  interferon product approved by state regulator  for  clinical usage against              respiratory viral infection in the world

           2.The only interferon product which safety is confirmed  in children

           3.The only interferon product with patents for compatibility with common inhalation drugs

Current stage: Phase II clinical trials